These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 15984959

  • 1. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
    Lichtenstein GR.
    Am J Gastroenterol; 2005 Jul; 100(7):1433-5. PubMed ID: 15984959
    [No Abstract] [Full Text] [Related]

  • 2. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time.
    Loftus EV.
    Am J Gastroenterol; 2005 Jul; 100(7):1435-8. PubMed ID: 15984960
    [No Abstract] [Full Text] [Related]

  • 3. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
    Hanauer SB.
    Am J Gastroenterol; 2005 Jul; 100(7):1438-9. PubMed ID: 15984961
    [No Abstract] [Full Text] [Related]

  • 4. Guidelines for treatment with infliximab for Crohn's disease.
    Hommes DW, Oldenburg B, van Bodegraven AA, van Hogezand RA, de Jong DJ, Romberg-Camps MJ, van der Woude J, Dijkstra G, Dutch Initiative on Crohn and Colitis (ICC).
    Neth J Med; 2006 Jul; 64(7):219-29. PubMed ID: 16929083
    [Abstract] [Full Text] [Related]

  • 5. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 6. [Indications and results of infliximab in Crohn's disease].
    Karoui S, Boubaker J, Filali A.
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [Abstract] [Full Text] [Related]

  • 7. Timing infliximab therapy in pediatric Crohn's disease.
    Kirschner BS, Huo D.
    Gastroenterology; 2007 Mar; 132(3):1167-70. PubMed ID: 17383435
    [No Abstract] [Full Text] [Related]

  • 8. Immunogenicity of infliximab in Crohn's disease.
    Hanauer SB.
    N Engl J Med; 2003 May 22; 348(21):2155-6; author reply 2155-6. PubMed ID: 12761378
    [No Abstract] [Full Text] [Related]

  • 9. Induction of pustular lesions during infliximab therapy for Crohn's disease.
    Pérez-Pérez L, Caeiro JL, Fabeiro JM, Allegue F, Zulaica A.
    Acta Derm Venereol; 2008 May 22; 88(3):292-3. PubMed ID: 18480940
    [No Abstract] [Full Text] [Related]

  • 10. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance.
    Francis G, Duggan A.
    Gastroenterology; 2008 Dec 22; 135(6):2156-7. PubMed ID: 19013168
    [No Abstract] [Full Text] [Related]

  • 11. Maintenance infliximab infusions forever?
    Lee SD, Surawicz CM.
    Am J Gastroenterol; 2002 Nov 22; 97(11):2917-8. PubMed ID: 12425570
    [No Abstract] [Full Text] [Related]

  • 12. Closing fistulas in Crohn's disease--should the accent be on maintenance or safety?
    Fiocchi C.
    N Engl J Med; 2004 Feb 26; 350(9):934-6. PubMed ID: 14985492
    [No Abstract] [Full Text] [Related]

  • 13. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.
    Chaparro M, Panes J, García V, Mañosa M, Esteve M, Merino O, Andreu M, Gutierrez A, Gomollón F, Cabriada JL, Montoro MA, Mendoza JL, Nos P, Gisbert JP.
    J Clin Gastroenterol; 2011 Feb 26; 45(2):113-8. PubMed ID: 21242747
    [Abstract] [Full Text] [Related]

  • 14. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize.
    Sandborn WJ.
    Gastroenterology; 2003 Apr 26; 124(4):1140-5. PubMed ID: 12671907
    [No Abstract] [Full Text] [Related]

  • 15. The Dutch guidelines for treatment with infliximab for Crohn's disease.
    Vermeire S.
    Neth J Med; 2006 Apr 26; 64(7):210-1. PubMed ID: 16929081
    [No Abstract] [Full Text] [Related]

  • 16. Complications of infliximab therapy in children and adolescents affected by Crohn's disease.
    Diamanti A, Papadatou B, Knafelz D, Gambarara M, Ferretti F, Castro M.
    Am J Gastroenterol; 2003 Dec 26; 98(12):2812-3. PubMed ID: 14687847
    [No Abstract] [Full Text] [Related]

  • 17. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
    Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB.
    Gastrointest Endosc; 2006 Mar 26; 63(3):433-42; quiz 464. PubMed ID: 16500392
    [Abstract] [Full Text] [Related]

  • 18. Mucosal healing in Crohn's disease: what you see is what you get?
    Mahadevan U.
    Gastrointest Endosc; 2006 Mar 26; 63(3):443-4. PubMed ID: 16500393
    [No Abstract] [Full Text] [Related]

  • 19. Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab.
    Moss AC, Treister NS, Marsee DK, Cheifetz AS.
    Gastroenterology; 2007 Feb 26; 132(2):488, 829. PubMed ID: 17261307
    [No Abstract] [Full Text] [Related]

  • 20. Combination therapy with infliximab and immunomodulators: is the glass half empty?
    Deshpande AR, Abreu MT.
    Gastroenterology; 2008 Jun 26; 134(7):2161-3. PubMed ID: 18482585
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.